Literature DB >> 11584013

Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing.

S R Lim1, K J Hertel.   

Abstract

Spinal muscular atrophy is caused by the loss of functional survival motor neuron (SMN1) alleles. A translationally silent nucleotide transition in the duplicated copy of the gene (SMN2) leads to exon 7 skipping and expression of a nonfunctional gene product. It has been suggested that differential SMN2 splicing is caused by the disruption of an exonic splicing enhancer. Here we show that the single nucleotide difference reduces the intrinsic strength of the 3' splice site of exon 7 2-fold, whereas the strength of the 5' splice site of the exon 7 is not affected. Thus, a decrease in splice site strength is magnified in the context of competing exons. These data suggest that lower levels of exon 7 definition not only reduce intron 6 removal but, more importantly, increase the efficiency of the competing exon 7 skipping pathway. Antisense oligonucleotides were tested to modulate exon 7 inclusion, which contains the authentic translation stop codon. Oligonucleotides directed toward the 3' splice site of exon 8 were shown to alter SMN2 splicing in favor of exon 7 inclusion. These results suggest that antisense oligonucleotides could be used as a therapeutic strategy to counteract the progression of SMA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584013     DOI: 10.1074/jbc.M107632200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes.

Authors:  Natalia N Singh; Elliot J Androphy; Ravindra N Singh
Journal:  RNA       Date:  2004-08       Impact factor: 4.942

2.  The Silent Sway of Splicing by Synonymous Substitutions.

Authors:  William F Mueller; Liza S Z Larsen; Angela Garibaldi; G Wesley Hatfield; Klemens J Hertel
Journal:  J Biol Chem       Date:  2015-09-30       Impact factor: 5.157

3.  Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.

Authors:  Natalia N Singh; Brian M Lee; Ravindra N Singh
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

Review 4.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

5.  hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.

Authors:  Akio Masuda; Xin-Ming Shen; Mikako Ito; Tohru Matsuura; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2008-09-20       Impact factor: 6.150

6.  Competing upstream 5' splice sites enhance the rate of proximal splicing.

Authors:  Martin J Hicks; William F Mueller; Peter J Shepard; Klemens J Hertel
Journal:  Mol Cell Biol       Date:  2010-02-01       Impact factor: 4.272

Review 7.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

8.  Enhancer-dependent 5'-splice site control of fruitless pre-mRNA splicing.

Authors:  Bianca J Lam; Arati Bakshi; Fatma Y Ekinci; Jenny Webb; Brenton R Graveley; Klemens J Hertel
Journal:  J Biol Chem       Date:  2003-03-19       Impact factor: 5.157

9.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts.

Authors:  Leigh A Skordis; Matthew G Dunckley; Baigong Yue; Ian C Eperon; Francesco Muntoni
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

10.  Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy.

Authors:  Tristan H Coady; Christian L Lorson
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.